| Literature DB >> 32105810 |
Christopher D Goodman1, Suzan F M Nijman2, Suresh Senan2, Esther J Nossent2, Christopher J Ryerson3, Inderdeep Dhaliwal1, X Melody Qu1, Joanna Laba1, George B Rodrigues1, David A Palma4.
Abstract
Interstitial lung disease (ILD) is a term used to describe a heterogeneous group of lung disorders with characteristic clinical and imaging features. Patients with ILD are at an increased risk of developing NSCLC, which is frequently medically comorbid, often precluding operative management. In this scenario, radiotherapy (RT) is generally recommended; however, ILD is known to increase the risk of RT-related toxicity. Recommendations for treatment with appropriately individualized risks and benefits are thus dependent on integration of patient-, ILD-, and cancer-specific factors. We aim to provide an overview of ILD for the thoracic oncologist, an assessment of risk of thoracic RT in patients with ILD, and evidence-based recommendations for treatment in a variety of clinical scenarios.Entities:
Keywords: Clinical decision making; Interstitial lung disease; Thoracic radiation; Toxicity
Mesh:
Year: 2020 PMID: 32105810 DOI: 10.1016/j.jtho.2020.02.005
Source DB: PubMed Journal: J Thorac Oncol ISSN: 1556-0864 Impact factor: 15.609